In vitro prostanoid release from spinal cord following XXXX : effects of substance P, @entity143 and @entity2951 .

@entity32 @entity10133 @entity1931 @entity1024 @entity2951 @entity4563 @entity1421 @entity5018 @entity16325 @entity3448 @entity143 @entity6784 @entity35 @entity9077
1. Spinal prostanoids are implicated in the development of @entity1931 after @entity6784 , but the specific prostanoid species that are involved are presently unknown. The current study used an in vitro spinal superfusion model to investigate the effect of substance @entity10133 ), @entity1024 ( @entity143 ), and @entity2951 on multiple prostanoid release from dorsal spinal cord of naive @entity35 as well as @entity35 that underwent peripheral @entity32 (knee joint @entity4563 /carrageenan). 2. In naive @entity35 spinal cords, @entity1421 and @entity9077 , but not @entity3448 , levels were increased after inclusion of SP, @entity143 , or @entity2951 in the perfusion medium. 3. Basal @entity1421 levels from spinal cords of animals that underwent 5-72 h of @entity32 were elevated relative to age-matched naive cohorts. The time course of this increase in basal @entity1421 levels coincided with @entity32 , as assessed by knee joint circumference. Basal @entity9077 levels were not elevated after injury. 4. From this @entity32 -evoked increase in basal @entity1421 levels, SP and @entity2951 significantly increased spinal @entity1421 release in a dose-dependent fashion. @entity2951 -evoked increases were blocked dose-dependently by inclusion of S(+) @entity5018 in the @entity2951 -containing perfusate. 5. These data suggest a role for spinal @entity1421 and @entity16325 activation in the development of @entity1931 after injury and demonstrate that this relationship is upregulated in response to peripheral tissue @entity32 .
